Logo Image

Duchenne Muscular Dystrophy

Latest News

Sarah Boyce, president and CEO, Avidity Biosciences | Image Credit: Avidity Biosciences
October 9th 2023
Avidity Biosciences Gains FDA Orphan Drug Designation for Patients With DMD

Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping (DMD44).

June 22nd 2023

FDA Approves Delandistrogene Moxeparvovec, First Gene Therapy to Treat Duchenne Muscular Dystrophy

image of children
September 21st 2022

Balancing Hopes for a Cure for SMA, DMD With Realistic Expectations

September 12th 2020

Researchers Outline Promising Future for SMA, DMD With Emergence of Gene Therapies, ASOs

June 15th 2020

Researchers Try to Update Prevalence of Duchenne Muscular Dystrophy